Claims for Patent: 9,248,172

Summary for Patent: 9,248,172

Title:	Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
Abstract:	The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an .alpha.-2-macroglobulin (.alpha.2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an .alpha.2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or .alpha.2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
Inventor(s):	Srivastava; Pramod K. (Avon, CT), Li; Zihai (Mount Pleasant, SC)
Assignee:	University of Connecticut Health Center (Farmington, CT)
Application Number:	14/043,666
Patent Claims:	1. A method of treating a cancer in a subject in need thereof, the method comprising: administering to the subject Bevacizumab, wherein the subject is a candidate for receiving Bevacizumab to treat the cancer, and wherein the subject has been administered a purified heat shock protein preparation comprising a heat shock protein-peptide complex comprising a heat shock protein covalently or noncovalently attached to an antigenic peptide, wherein the antigenic peptide displays antigenicity of an antigen of the cancer. 2. The method of claim 1, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes that comprise one or more of hsp70, hsp90, hsp110, gp96, grp170, and calreticulin. 3. The method of claim 2, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes that comprise gp96. 4. The method of claim 1, wherein the subject receives further administrations of Bevacizumab and the purified heat shock protein preparation, wherein the administrations are repeated for up to 12 cycles. 5. The method of claim 1, wherein the subject is administered the purified heat shock protein preparation once a week for the first 4 weeks after an initial administration of the purified heat shock protein preparation. 6. The method of claim 5, wherein the subject is administered the purified heat shock protein preparation once every other week after the first 4 weeks of administration of the purified heat shock protein preparation. 7. The method of claim 1 further comprising administering to the subject radiation therapy. 8. The method of claim 1, wherein the Bevacizumab is administered for a first period of time, followed by a further administration of the purified heat shock protein preparation for a second period of time, wherein this sequential administration is repeated. 9. The method of claim 1, wherein Bevacizumab is administered concurrently with further administrations of the purified heat shock protein preparation. 10. The method of claim 1, wherein the Bevacizumab is cyclically administered with purified heat shock protein preparation. 11. The method of claim 1, wherein the purified heat shock protein preparation is autologous to the subject. 12. The method of claim 1, wherein the subject is human. 13. The method of claim 12, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes isolated from cells of the cancer. 14. The method of claim 1, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes comprising heat shock proteins non-covalently attached to antigenic peptides. 15. The method of claim 1, wherein the antigenic peptide displays antigenicity of a tumor-specific antigen or a tumor-associated antigen of the cancer. 16. The method of claim 1, wherein the cancer is a relapse form of cancer. 17. The method of claim 16, wherein the subject is human and wherein the antigenic peptide displays antigenicity of a tumor-specific antigen or a tumor-associated antigen of the cancer. 18. The method of claim 1, wherein the Bevacizumab is administered intravenously. 19. The method of claim 18, wherein the purified heat shock protein preparation is administered intradermally. 20. The method of claim 1, wherein the purified heat shock protein preparation is administered intradermally.

Details for Patent 9,248,172

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2022-04-25